Tuesday, February 27, 2024
Luminary stands out as a clinical stage CAR-T therapy company utilizing a unique allogeneic manufacturing platform. Our CAR and TCR development revolve around gamma delta cells, giving our allogeneic therapeutics a distinct advantage. What sets our therapies apart is the inclusion of both Vẟ1 and Vẟ2 cells, in the final drug products, combining the innate and adaptive cancer clearing powers. We are actively developing multiple solid tumor targets and employ proprietary co-stimulatory signaling methods to ensure T-Cell persistence enhancing the effectiveness of our therapies. Furthermore, our Ligand based BAFF CAR for hematologic cancers boasts three antigen receptors, specifically designed to overcome antigen escape.
CEO/Top Company Official
Lead Product in Development
LMY-232 -- Dual Targeting CAR CSPG4/CD70 for Cholangiocarcinoma, Renal & Esophageal Cancers
Development Phase of Primary Product
Number Of Unlicensed Products